课题基金 / 基金详情

项目摘要

项目成果

Nancy J. Brown的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Advances in molecular medicine, genomics, proteomics and bioinformatics have enhanced our understanding of inter-individual variability in susceptibility to disease, in expression of disease, and in beneficial and adverse responses to therapies. Vanderbilt University Medical Center has prioritized personalized health and healthcare as a research goal, with the aim of developing methodologies to deliver new information - such as genetic, genomic, or proteomic data - to clinical decision-making in patient care. With existing strengths in Clinical Pharmacology and Drug Discovery, Proteomics, Imaging, Genetics and Bioinformatics, we believe Vanderbilt is poised to impact on personalized healthcare in the United States. Vanderbilt has made substantial investments in genetic and genomic science, in proteomics and biomarker discovery, in clinical information science, and in the creation of BioVU (a DNA biobank exceeding 54,000 samples already) and of the Synthetic Derivative of its electronic health record. Realizing the potential of these investments requires continued recruitment of and investment in a multidisciplinary team of young investigators with expertise in clinical and basic pharmacology, mass spectrometry, clinical and basic genetics, informatics, and genetic epidemiology and biostatistics. This need comes at a time when the economic climate and decreases in the Vanderbilt endowment have necessitated a slowing of hiring. The goal of the Vanderbilt Personalized Medicine Core, therefore, is to support the hiring and career development of junior faculty with expertise in these areas, who can exploit the resources and environment at Vanderbilt to impact on personalized medicine. Dr. Nancy J. Brown, Chief of the Division of Clinical Pharmacology and Associate Dean for Clinical and Translational Scientist Development will direct the Core. Dr. Dan M. Roden, Director of the Dates Institute for Experimental Therapeutics and Assistant Vice- Chancellor for Personalized Medicine; Dr. Dan Masys, Professor and Chair of the Department of Biomedical Informatics; Dr. Jonathan Haines, Director, Center for Human Genetics Research; and Dr. Katherine E. Hartmann, Director, Vanderbilt University Evidence-based Practice Center and Deputy Director, Institute for Medicine and Public Health will serve to oversee the selection, development and conduct of projects. The Core will leverage existing infrastructure for career development and for tracking the impact of faculty members on multidisciplinary research in personalized medicine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition
  • 批准号:
    10755424
  • 项目类别:
  • 资助金额:
    $49.2万
  • 财政年份:
    2020
  • 负责人:
    Nancy J. Brown
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: